-
公开(公告)号：US6004561A
公开(公告)日：1999-12-21
申请号：US797629
申请日：1997-02-07
IPC分类号： A61K39/00 , C07K14/02 , C12N7/01 , C12N15/51 , C12P21/08 , G01N33/576 , C12Q1/70 , A61K39/29 , G01N33/53
CPC分类号： C07K14/005 , G01N33/5764 , A61K2039/525 , A61K39/00 , C12N2730/10122 , Y10S435/975 , Y10S436/82
摘要： The present invention relates to methods of producing recombinant molecules including the nucleotide sequence for the structure of the preS1 region of the surface glycoprotein of the hepatitis B virus, and to compositions of the molecules. Compositions of the recombinant molecules may include a promoter and a marker gene. Cloning vectors are used to incorporate the recombinant molecules into hosts. Cells infected with the chimeric vaccinia produce high levels of preS1 protein. Isolation and purification of the preS1-containing protein is facilitated by the use of a recombinant molecule in which the myristylation site has been deleted by a modification of the nucleotide sequence. The purified preS1-containing protein is useful for development of vaccines, diagnostic kits and therapies.
-
2.发明授权High level expression of polypeptide that contains modified preS1 region of hepatitis B virus large antigen 失效含有修饰的preS1区域的乙型肝炎病毒大抗原的多肽的高水平表达
公开(公告)号：US6077691A
公开(公告)日：2000-06-20
申请号：US796415
申请日：1997-02-06
IPC分类号： A61K39/00 , C07K14/02 , C12N7/01 , C12N15/51 , C12P21/08 , G01N33/576 , C12P21/00 , A61K39/29
CPC分类号： C07K14/005 , G01N33/5764 , A61K2039/525 , A61K39/00 , C12N2730/10122 , Y10S435/975 , Y10S436/82
摘要： The present invention relates to methods of producing recombinant molecules including the nucleotide sequence for the structure of the preS1 region of the surface glycoprotein of the hepatitis B virus, and to compositions of the molecules. Compositions of the recombinant molecules may include a promoter and a marker gene. Cloning vectors are used to incorporate the recombinant molecules into hosts. Cells infected with the chimeric vaccinia produce high levels of preS1 protein. Isolation and purification of the preS1-containing protein is facilitated by the use of a recombinant molecule in which the myristylation site has been deleted by a modification of the nucleotide sequence. The purified preS1-containing protein is useful for development of vaccines, diagnostic kits and therapies.
摘要翻译： 本发明涉及生产重组分子的方法，包括用于乙型肝炎病毒的表面糖蛋白的前S1区域的结构的核苷酸序列和分子的组合物。 重组分子的组成可以包括启动子和标记基因。 克隆载体用于将重组分子并入宿主体内。 感染了嵌合牛痘的细胞产生高水平的preS1蛋白。 通过使用重组分子促进含PreS1的蛋白质的分离和纯化，其中已经通过核苷酸序列的修饰将肉豆蔻基化位点缺失。 纯化的含PreS1的蛋白质可用于开发疫苗，诊断试剂盒和疗法。
-
公开(公告)号：US5770212A
公开(公告)日：1998-06-23
申请号：US802985
申请日：1997-02-21
IPC分类号： A01K67/027 , A61K39/00 , C07K14/07 , C07K14/16 , C12N5/10 , C12N7/00 , C12N7/01 , C12N15/09 , C12N15/39 , C12N15/863 , C12R1/92 , A61K39/285 , A61K39/002 , A61K39/02 , A61K39/12 , A61K39/275
CPC分类号： C12N15/86 , C07K14/005 , A01K2217/05 , A61K39/00 , C12N2710/24122 , C12N2710/24143 , C12N2740/16222 , C12N2830/00 , C12N2830/002 , C12N2830/15 , C12N2830/42 , C12N2830/55 , C12N2830/60 , C12N2840/203
摘要： Defective poxviruses that lack a function imparted by an essential region of its parental poxvirus are provided for protein production and vaccination. A DNA polynucleotide encoding a protein is inserted into the defective poxvirus and placed under transcriptional control of a promoter. The defective poxvirus is viable when the lost function of the essential region is complemented by a host cell, transgenic animal or helper virus.
摘要翻译： 提供缺乏由其亲本痘病毒的必需区域赋予的功能的缺陷痘病毒用于蛋白质生产和疫苗接种。 将编码蛋白质的DNA多核苷酸插入有缺陷的痘病毒中并置于启动子的转录控制下。 当基因区域的功能丧失由宿主细胞，转基因动物或辅助病毒补充时，有缺陷的痘病毒是可行的。
-
公开(公告)号：US5766882A
公开(公告)日：1998-06-16
申请号：US616133
申请日：1996-03-14
IPC分类号： A01K67/027 , A61K39/00 , C07K14/07 , C07K14/16 , C12N5/10 , C12N7/00 , C12N7/01 , C12N15/09 , C12N15/39 , C12N15/863 , C12R1/92 , C12N5/00 , C12N15/00 , C12P21/06
CPC分类号： C12N15/86 , C07K14/005 , A01K2217/05 , A61K39/00 , C12N2710/24122 , C12N2710/24143 , C12N2740/16222 , C12N2830/00 , C12N2830/002 , C12N2830/15 , C12N2830/42 , C12N2830/55 , C12N2830/60 , C12N2840/203
摘要： Defective poxviruses that lack a function imparted by an essential region of its parental poxvirus are provided for protein production and vaccination. A DNA polynucleotide encoding a protein is inserted into the defective poxvirus and placed under transcriptional control of a promoter. The defective poxvirus is viable when the lost function of the essential region is complemented by a host cell, transgenic animal or helper virus.
摘要翻译： 提供缺乏由其亲本痘病毒的必需区域赋予的功能的缺陷痘病毒用于蛋白质生产和疫苗接种。 将编码蛋白质的DNA多核苷酸插入有缺陷的痘病毒中并置于启动子的转录控制下。 当基因区域的功能丧失由宿主细胞，转基因动物或辅助病毒补充时，有缺陷的痘病毒是可行的。
-
公开(公告)号：US6086871A
公开(公告)日：2000-07-11
申请号：US952967
申请日：1998-01-26
IPC分类号： C12N15/09 , A61K38/00 , A61K38/46 , A61K38/55 , A61P7/02 , C12N9/64 , C12N9/74 , C12N15/57 , C12P21/04 , C12Q1/56 , G01N33/53 , G01N33/86 , A61K38/48 , C12N1/20 , C12N15/00
CPC分类号： C12N9/6424 , C12N9/6429 , C12Y304/21005 , G01N33/86 , A61K38/00 , G01N2333/974
摘要： The invention relates to new prothrombin mutants or derivatives thereof which comprise one or more changes in their protein sequence as compared to natural protein, are either inactive or have an activity of approximately 10% at the most, preferably approximately 0.25% at the most, of the natural protein and which have a binding capacity relative to natural ligands (natural or synthetic anticoagulants) substantially corresponding to that of the natural protein. Furthermore, the use of mutated prothrombin mutants or derivatives, respectively, as pharmaceutical preparations is described.
摘要翻译： PCT No.PCT / AT96 / 00105 Sec。 371日期1998年1月26日 102（e）1998年1月26日PCT PCT 1996年6月12日PCT公布。 出版物WO96 / 41868 日期1996年12月27日本发明涉及与天然蛋白相比包含其蛋白质序列的一个或多个变化的新的凝血酶原突变体或其衍生物，其为无活性的或具有最多约10％的活性，优选约0.25％ 最多的天然蛋白质，并且相对于天然配体（天然或合成抗凝剂）具有与天然蛋白质天然配体相当的结合能力。 此外，描述了分别使用突变的凝血酶原突变体或衍生物作为药物制剂。
-
-
-
-
搜索结果
5 条记录 (耗时 0.016 秒)